On March 28th Sabine Fuchs, Ibrahim Aridsasmita and Indi Joore received an innovation voucher by Utrecht Holdings. We were wondering how things are going, so we asked them 5 questions.

1. Short summary of the invention and voucher.

We have developed a novel, human liver model in a dish called hepatocyte-like liver organoid (HeLLO). We validated HeLLOs to predict 53% of liver toxic compounds compared to 27% for the gold-standard. We will develop an automated drug-liver-toxicity screening service using the HeLLO liver toxicity assay. This will help pharmaceutical companies reduce liver toxic compounds in the drug development pipelines. As such, our service results in safer drug development and earlier detection of liver toxic compounds streamlining drug development, decreasing development costs.

2. Can you provide an update on where you are now? Are there any new results?

We have further validated our underlying technology and will be attending key stakeholder events to share our findings.

3. How has the voucher contributed to the next steps?

The voucher has allowed us to undertake valorizing steps, such as validating our technology, engaging with prospective customers and visiting prominent toxicology conferences.

4. How did Utrecht Holdings (the Business Developer) help you?

Our business developer at Utrecht Holdings, Danielle Counotte, has helped us by aiding in several grant applications, forwarding important entrepreneurial opportunities and by initiating the licensing process.

5. Where do you want to be in two years?

We want to have secured four pharmaceutical customers on our diverse liver toxicity testing platform.

We wish the team all the best in reaching their goals!